Results of a Multicenter Prospective Observational Study “ALLIANCE” on the Impact of Rifaximin and Trimebutine on Quality of Life and the Course of Uncomplicated Diverticular Disease in Outpatient Clinical Practice

Aim : to evaluate the impact of the drugs Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) on symptom severity and quality of life in patients with uncomplicated diverticular disease. Materials and methods. A multicenter non-interventional prospective observational study was conducted, involving 100 patients diagnosed with uncomplicated diverticular disease. Patients received Alfaxim® (rifaximin) at 400 mg 2–3 times daily for 7 days monthly over 6 months and Neobutin Retard® (trimebutine) at 300 mg twice daily for 4 weeks, in addition to standard therapy. Symptom severity (abdominal pain, constipation, diarrhea, bloating, tenesmus) was assessed using a 3-point scale. Quality of life was evaluated using the SF-12 questionnaire. Patient adherence to treatment was measured using the Morisky — Green Compliance Scale. Results . Cyclic therapy with Alfaxim® and Neobutin Retard® showed statistically significant (p < 0.001) positive effects on all assessed symptoms. Over half of the patients (55 %) achieved remission by the end of the observation period. Analysis of SF-12 scores revealed a significant improvement in quality of life (p < 0.001). Most patients demonstrated high treatment adherence throughout the study. No adverse events were recorded during the observation period. Conclusions. The use of Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) reduces symptom severity and improves quality of life in patients with uncomplicated diverticular disease. The drugs have a favorable safety profile.